Soligenix Inc SNGX announced a publication describing the preclinical efficacy of a novel, single-vial, bivalent vaccine providing 100% protection against Sudan ebolavirus (SUDV) and Marburg marburgvirus (MARV) infections.
The vaccine candidate has been previously demonstrated to be stable to high-temperature storage for at least two years at 40 degrees Celsius (104 degrees Fahrenheit).
Currently, there are no approved vaccines or therapeutics for either SUDV or MARV infections.
The published paper describes the potency of the bivalent formulation against both viruses, demonstrating 100% protection in the most rigorous non-human primate challenge models.
Under the company's Public Health Solutions business segment, ongoing collaborations with Dr. Lehrer have demonstrated the feasibility of developing thermally stable subunit protein vaccine formulations for filoviruses.
Work to date has demonstrated the compatibility of lyophilizing both antigen and adjuvant in the same vial, with reconstitution with sterile water for injection immediately before use.
In November, the FDA cleared Soligenix's Investigational New Drug (IND) application for a Phase 2a clinical trial for SGX945 (dusquetide) for aphthous ulcers in Behçet's disease, a rare vasculitic disorder that can affect small, medium, and large vessels.
Price Action: SNGX shares are up 33.20% at $1.01 on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
